NVCR241220P7500
- 0.13
- 0.000.00%
Novocure Newsroom
Novocure to Participate in Upcoming Investor Conferences
Novocure Secures FDA Approval for Add-ons to Brain Cancer Treatment Wearable
NovoCure's Buy Rating Backed by FDA Approval and Strategic Growth Plans Amidst Potential Risks
The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of...
Express News | Novocure Ltd - to Convert Optune Gio Users to New Hfe Arrays by Mid-2025
Express News | FDA Approves Novocure’s Innovative Hfe Transducer Arrays for Use With Optune Gio® for Glioblastoma
Novocure Participates in a Conference Call With JPMorgan
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
NovoCure's Strong Q3 and Leadership Changes in 2024
NovoCure Analyst Ratings
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript Summary
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $30
Novocure | 8-K: Novocure Reports Third Quarter 2024 Financial Results
Express News | Novocure Ltd Q3 Shr View $-0.33 -- LSEG IBES Data
Express News | Novocure Ltd: Current CFO, Ashley Cordova, Becomes CEO
Novocure | 10-Q: Q3 2024 Earnings Report
Express News | Novocure Ltd - Brackmann to Transition to CFO on January 1, 2025
Express News | Novocure Appoints Christoph Brackmann as Chief Financial Officer
Express News | NovoCure Q3 2024 GAAP EPS $(0.28) Beats $(0.33) Estimate, Sales $155.09M Beat $143.95M Estimate